Oral S2-Ag85 DNA Vaccine Activated Intestinal Cell dsDNA and RNA Sensors to Promote the Presentation of Intestinal Antigen

Dang, Sheng; Sui, Xin; Wu, Dongxing; Wen, Sijian; Song, Yang; Chen, Zeliang; Zhai, Jingbo

doi:10.1155/2022/7200379

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, nucleic acid vaccines are safer than viral and bacterial vaccines, have a low likelihood of genome integration, and do not elicit an immune response towards the vectors. Plasmid DNA derived from bacterial DNA encodes an antigen but might also provide TLR9 agonist signals and activate other cytoplasmic DNA-sensing molecules such as AIM2, RIG-I and STING 125 ; similarly, RNA might activate other TLR sensors such as TLR3 and TLR7 (refs. 126 , 127 ).…”

Section: Antigen-specific Vaccinesmentioning

confidence: 99%

Vaccines as treatments for prostate cancer

2023

View full text Add to dashboard Cite

Prostate cancer is a leading cause of death in men worldwide. For over 30 years, growing interest has focused on the development of vaccines as treatments for prostate cancer, with the goal of using vaccines to activate immune cells capable of targeting prostate cancer to either eradicate recurrent disease or at least delay disease progression. This interest has been prompted by the prevalence and long natural history of the disease and by the fact that the prostate is an expendable organ. Thus, an immune response elicited by vaccination might not need to target the tumour uniquely but could theoretically target any prostate tissue. To date, different vaccine approaches and targets for prostate cancer have been evaluated in clinical trials. Overall, five approaches have been assessed in randomized phase III trials and sipuleucel-T was approved as a treatment for metastatic castration-resistant prostate cancer, being the only vaccine approved to date by the FDA as a treatment for cancer. Most vaccine approaches showed safety and some evidence of immunological activity but had poor clinical activity when used as monotherapies. However, increased activity has been observed when these vaccines were used in combination with other immune-modulating therapies. This evidence suggests that, in the future, prostate cancer vaccines might be used to activate and expand tumour-specific T cells as part of combination approaches with agents that target tumour-associated immune mechanisms of resistance.

show abstract

Section: Antigen-specific Vaccinesmentioning

confidence: 99%

Vaccines as treatments for prostate cancer

2023

View full text Add to dashboard Cite

show abstract

Exploring the immunogenicity of Rv2201-519: A T-cell epitope-based antigen derived from Mycobacterium tuberculosis AsnB with implications for tuberculosis infection detection and vaccine development

Luan,

Fan,

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Ag85a-S2 Activates cGAS-STING Signaling Pathway in Intestinal Mucosal Cells

Dang

Wen

et al. 2022

Vaccines

View full text Add to dashboard Cite

Brucellosis is a zoonotic disease caused by Gram-negative bacteria. Most of the brucellosis vaccines in the application are whole-bacteria vaccines. Live-attenuated vaccines are widely used for brucellosis prevention in sheep, goats, pigs, and cattle. Thus, there is also a need for an adjuvanted vaccine for human brucellosis, because the attenuated Brucella vaccines now utilized in animals cause human illness. Here, we developed a live-attenuated Brucella suis strain 2 vaccine (S2) adjuvanted with Ag85a (Ag85a-S2). We found that Ag85a-S2 activated cGAS-STING pathways both in intestinal mucosal cells in vivo and in the BMDM and U937 cell line in vitro. We demonstrated that the cGAS knockout significantly downregulated the abundance of interferon and other cytokines induced by Ag85a-S2. Moreover, Ag85a-S2 triggered a stronger cellular immune response compared to S2 alone. In sum, Ag85a-S2-mediated enhancement of immune responses was at least partially dependent on the cGAS-STING pathway. Our results provide a new candidate for preventing Brucella pathogens from livestock, which might reduce the dosage and potential toxicity compared to S2.

show abstract

Oral S2-Ag85 DNA Vaccine Activated Intestinal Cell dsDNA and RNA Sensors to Promote the Presentation of Intestinal Antigen

Cited by 3 publications

References 24 publications

Vaccines as treatments for prostate cancer

Vaccines as treatments for prostate cancer

Exploring the immunogenicity of Rv2201-519: A T-cell epitope-based antigen derived from Mycobacterium tuberculosis AsnB with implications for tuberculosis infection detection and vaccine development

Ag85a-S2 Activates cGAS-STING Signaling Pathway in Intestinal Mucosal Cells

Contact Info

Product

Resources

About